The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection.
作者信息
Song Eingun James, Whitman Patrick, Samsel Jonmichael
机构信息
North Sound Dermatology, Mill Creek, Washington.
Silver Falls Dermatology, Salem, Oregon.
出版信息
JAAD Case Rep. 2020 Dec 14;8:37-39. doi: 10.1016/j.jdcr.2020.12.006. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection.
JAAD Case Rep. 2020 Dec 14;8:37-39. doi: 10.1016/j.jdcr.2020.12.006. eCollection 2021 Feb.
2
The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series.
JAAD Case Rep. 2022 Oct 4;30:1-4. doi: 10.1016/j.jdcr.2022.09.023. eCollection 2022 Dec.
3
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
4
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.
5
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1.
6
Safety of guselkumab in hepatitis B virus infection.
Dermatol Online J. 2019 Oct 15;25(10):13030/qt47h636rx.
7
Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Ann Pharmacother. 2018 Apr;52(4):380-387. doi: 10.1177/1060028017743268. Epub 2017 Nov 14.
8
Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
Am J Clin Dermatol. 2019 Dec;20(6):829-845. doi: 10.1007/s40257-019-00457-3.
9
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045.
10
Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab.
J Drugs Dermatol. 2012 Dec;11(12):1498-501.
引用本文的文献
1
Guselkumab - In Psoriasis and Beyond.
Dermatol Pract Concept. 2024 Jul 1;14(3):e2024181. doi: 10.5826/dpc.1403a181.
2
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.
Pediatric Health Med Ther. 2023 Nov 14;14:435-451. doi: 10.2147/PHMT.S389108. eCollection 2023.
3
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection.
Clin Cosmet Investig Dermatol. 2023 Feb 5;16:369-373. doi: 10.2147/CCID.S403294. eCollection 2023.
4
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
5
The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series.
JAAD Case Rep. 2022 Oct 4;30:1-4. doi: 10.1016/j.jdcr.2022.09.023. eCollection 2022 Dec.
6
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.
Biomedicines. 2022 Jan 21;10(2):228. doi: 10.3390/biomedicines10020228.
本文引用的文献
1
Safety of guselkumab in hepatitis B virus infection.
Dermatol Online J. 2019 Oct 15;25(10):13030/qt47h636rx.
2
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis.
JAAD Case Rep. 2019 Jan 25;5(2):150-152. doi: 10.1016/j.jdcr.2018.11.016. eCollection 2019 Feb.
3
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
4
Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
World J Gastroenterol. 2016 Jul 28;22(28):6444-55. doi: 10.3748/wjg.v22.i28.6444.
5
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
6
The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
Br J Dermatol. 2013 Dec;169(6):1295-303. doi: 10.1111/bjd.12461.
7
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045.
8
Tumor necrosis factor blockade and the risk of viral infection.
Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9.
9
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
Ann Rheum Dis. 2006 Aug;65(8):983-9. doi: 10.1136/ard.2005.043257. Epub 2006 Apr 20.
Zotero 插件